Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease
| Autor: | Lynne Timmis, J. R. B. Green, Hamish D. Duncan, Callum B. Pearce |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male medicine.medical_specialty Urea breath test Population Enzyme-Linked Immunosorbent Assay Gastroenterology Inflammatory bowel disease Helicobacter Infections Crohn Disease Sulfasalazine Internal medicine Prevalence medicine Humans In patient Prospective Studies Mesalamine education Irritable bowel syndrome education.field_of_study Helicobacter pylori Hepatology biology medicine.diagnostic_test business.industry Anti-Inflammatory Agents Non-Steroidal Middle Aged Inflammatory Bowel Diseases medicine.disease biology.organism_classification Ulcerative colitis digestive system diseases Anti-Bacterial Agents Breath Tests Colitis Ulcerative Female Gastritis medicine.symptom business medicine.drug |
| Zdroj: | European Journal of Gastroenterology & Hepatology. 12:439-443 |
| ISSN: | 0954-691X |
| Popis: | Objective To determine the prevalence of Helicobacter pylori in patients with inflammatory bowel disease (IBD) and compare this to the prevalence in a control population with non-organic bowel symptoms, and to investigate the effect of sulphasalazine and other 5-aminosalicylic acid (5-ASA) drugs on the prevalence of H. pylori in IBD patients. Design Prospective, controlled trial. Setting Gastroenterology out-patient department, City General Hospital, North Staffordshire Hospitals NHS Trust, Stoke-on-Trent. Participants The population comprised 51 patients with ulcerative colitis, 42 patients with Crohn's disease and 40 patients with irritable bowel syndrome as controls. Patients with X-ray- and/or biopsy-proven disease were eligible to be entered into the study. Interventions Subjects filled in a detailed questionnaire, were assessed for seropositivity of H. pylori and underwent a C13 urea breath test (UBT). Main outcome measures Seropositivity for H. pylori and a positive C13 UBT result Results A quarter of the irritable bowel syndrome controls were seropositive for H. pylori. Of the ulcerative colitis patients, 21.6% were currently H. pylori-positive on C13 UBT; 17.6% of the ulcerative colitis patients who had been previously treated with sulphasalazine were positive while 23.1% of the ulcerative colitis patients who had been treated with a non-sulphasalazine 5-ASA drug were positive. Of the Crohn's patients, 11.9% were currently H. pylori-positive; 3.6% of the Crohn's patients who had been previously treated with sulphasalazine were positive while 12.5% of the Crohn's patients who had been treated with a non-sulphasalazine 5-ASA drug were positive. Conclusions Patients with IBD and Crohn's disease in particular were less likely to be H. pylori-positive than controls. Sulphasalazine treatment further decreased the prevalence of H. pylori, although the reduced prevalence of H. pylori in IBD patients could not be accounted for by this alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|